NO20060219L - Forbindelser - Google Patents
ForbindelserInfo
- Publication number
- NO20060219L NO20060219L NO20060219A NO20060219A NO20060219L NO 20060219 L NO20060219 L NO 20060219L NO 20060219 A NO20060219 A NO 20060219A NO 20060219 A NO20060219 A NO 20060219A NO 20060219 L NO20060219 L NO 20060219L
- Authority
- NO
- Norway
- Prior art keywords
- ring
- optionally substituted
- heterobycyclic
- group
- unsaturated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Det beskrives en forbindelse av formel (I) hvor ring A og ring B er, (1) ring A er en valgfritt substituert umettet monosyklisk heterosyklisk ring, og ring B er en valgfritt substituert umettet monosyklisk heterosyklisk ring, en valgfritt substituert umettet fusjonert heterobisyklisk ring, eller en valgfritt substituert benzennng, (2) ring A er en valgfritt substituert benzenrmg, og ring B er en valgfritt substituert umettet monosyklisk heterosyklisk ring, en valgfritt substituert umettet fusjonert heterobisyklisk ring, eller en valgfritt substituert benzennng, eller (3) ring A er en valgfritt substituert umettet fusjonert heterobisyklisk ring, hvor -NR- gruppen og -CH2- gruppen er begge på den samme ring av den umettede fusjonerte heterobisykhske ring, og ring B er en valgfritt substituert monosyklisk umettet heterosyklisk ring, en valgfritt substituert umettet fusjonert heterobisyklisk ring, eller en valgfritt substituert benzenrmg, og R er et hydrogenatom, en lavere alkylgruppe, en lavere alkanoylgruppe eller en lavere alkoksykarbonylgruppe, eller et farmasøytisk akseptabelt salt derav, eller et prodrug derav
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49152303P | 2003-08-01 | 2003-08-01 | |
| PCT/JP2004/011311 WO2005012321A1 (en) | 2003-08-01 | 2004-07-30 | Novel compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20060219L true NO20060219L (no) | 2006-04-28 |
| NO333679B1 NO333679B1 (no) | 2013-08-05 |
Family
ID=34115512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20060219A NO333679B1 (no) | 2003-08-01 | 2006-01-16 | Forbindelse eller farmasoytisk salt derav, samt anvendelser og fremgangsmate for fremstilling av samme |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7521430B2 (no) |
| EP (1) | EP1654269B1 (no) |
| JP (1) | JP4717811B2 (no) |
| KR (1) | KR101101500B1 (no) |
| CN (2) | CN102060888A (no) |
| AU (1) | AU2004260760B2 (no) |
| BR (1) | BRPI0413233A (no) |
| CA (1) | CA2534022C (no) |
| EA (1) | EA011025B1 (no) |
| ES (1) | ES2527053T3 (no) |
| IL (1) | IL173051A (no) |
| MX (1) | MXPA06001273A (no) |
| NO (1) | NO333679B1 (no) |
| NZ (1) | NZ545305A (no) |
| TW (1) | TWI377209B (no) |
| UA (5) | UA86042C2 (no) |
| WO (1) | WO2005012321A1 (no) |
| ZA (2) | ZA200601686B (no) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8785403B2 (en) | 2003-08-01 | 2014-07-22 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
| JP4130466B2 (ja) * | 2003-08-01 | 2008-08-06 | 田辺三菱製薬株式会社 | 新規化合物 |
| TW200637869A (en) | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
| JP5073948B2 (ja) * | 2005-01-31 | 2012-11-14 | 田辺三菱製薬株式会社 | 医薬組成物 |
| AR053329A1 (es) * | 2005-01-31 | 2007-05-02 | Tanabe Seiyaku Co | Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt) |
| MY147375A (en) | 2005-01-31 | 2012-11-30 | Mitsubishi Tanabe Pharma Corp | Indole derivatives |
| TWI418556B (zh) * | 2006-07-27 | 2013-12-11 | Mitsubishi Tanabe Pharma Corp | 吲哚衍生物 |
| TWI499414B (zh) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法 |
| UY30730A1 (es) * | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| JP5298025B2 (ja) * | 2006-12-04 | 2013-09-25 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗糖尿病薬としてのチエニル含有グリコピラノシル誘導体 |
| US7846945B2 (en) * | 2007-03-08 | 2010-12-07 | Lexicon Pharmaceuticals, Inc. | Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use |
| NO2200606T3 (no) | 2007-09-10 | 2018-03-24 | ||
| CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| ES2526930T3 (es) | 2008-05-22 | 2015-01-16 | Astrazeneca Ab | Método para el tratamiento de la hiperuricemia empleando un inhibidor de SGLT2 y composición que contiene el mismo |
| WO2010023594A1 (en) | 2008-08-28 | 2010-03-04 | Pfizer Inc. | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
| US20110230403A1 (en) * | 2008-09-19 | 2011-09-22 | Novartis Ag | Glycoside derivatives and uses thereof |
| US9056850B2 (en) * | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
| US20110009347A1 (en) * | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
| CA2767258C (en) | 2009-07-10 | 2016-09-13 | Janssen Pharmaceutica Nv | Crystallisation process for 1-(.beta.-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene |
| BR112012008939B1 (pt) * | 2009-10-14 | 2021-06-22 | Janssen Pharmaceutica Nv | Processo para a preparação de compostos úteis como inibidores de sglt2 |
| DK2496583T3 (en) | 2009-11-02 | 2015-02-02 | Pfizer | Dioxa-bicyclo [3.2.1] octane-2,3,4-triol DERIVATIVES |
| MX339570B (es) | 2010-05-11 | 2016-05-31 | Janssen Pharmaceutica Nv | Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de transportadores de glucosa dependientes de sodio. |
| DK2697218T3 (en) | 2011-04-13 | 2016-07-25 | Janssen Pharmaceutica Nv | PROCESS FOR THE PREPARATION OF COMPOUNDS useful as inhibitors of SGLT2 |
| US9035044B2 (en) | 2011-05-09 | 2015-05-19 | Janssen Pharmaceutica Nv | L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
| ES2835828T3 (es) * | 2013-02-26 | 2021-06-23 | Mitsubishi Tanabe Pharma Corp | Procedimiento para producir a-halo-tetraacilglucosa |
| CN103896930B (zh) * | 2014-04-02 | 2016-08-17 | 安徽联创生物医药股份有限公司 | 卡格列净半水合物药用晶型的制备方法 |
| US9695159B2 (en) | 2014-05-27 | 2017-07-04 | Glenmark Pharmaceuticals Limited | Process for preparation of canagliflozin |
| CN104045673B (zh) * | 2014-06-06 | 2017-01-18 | 安徽省食品药品检验研究院 | 双‑三氮唑缀合的假二糖衍生物及其制备方法 |
| CN104478968A (zh) * | 2015-01-14 | 2015-04-01 | 佛山市赛维斯医药科技有限公司 | 含噻唑基的o-半乳糖苷衍生物、其制备方法和用途 |
| CN106188022A (zh) * | 2015-04-30 | 2016-12-07 | 上海医药工业研究院 | 伊格列净的制备方法 |
| US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
| EA202091324A1 (ru) | 2017-11-30 | 2020-10-05 | Идорсия Фармасьютиклз Лтд | Комбинация 4-пиримидинсульфамидного производного с ингибитором sglt-2 для лечения заболеваний, связанных с эндотелином |
| CA3105626A1 (en) | 2018-07-19 | 2020-01-23 | Astrazeneca Ab | Methods of treating hfpef employing dapagliflozin and compositions comprising the same |
| TW202220672A (zh) | 2020-07-27 | 2022-06-01 | 瑞典商阿斯特捷利康公司 | 用達格列淨治療慢性腎臟病之方法 |
| AU2022251165A1 (en) | 2021-04-01 | 2023-11-09 | Astrazeneca Uk Limited | Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition |
| CN118510504A (zh) | 2022-01-26 | 2024-08-16 | 阿斯利康(瑞典)有限公司 | 用于在治疗糖尿病前期或降低发展2型糖尿病的风险中使用的达格列净 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1075626B (de) * | 1960-02-18 | Farbwerke Hoechst Aktiengesellschaft vormals Meister Lucius &. Brunmg, Frankfurt/M | Verfahren zur Herstellung von wasserlöslichen chemotherapeutisch wirksamen Glykosiden | |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| NZ521369A (en) * | 2000-03-17 | 2004-07-30 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives |
| US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| AU9025701A (en) * | 2000-09-29 | 2002-04-15 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containingthe same |
| WO2002044192A1 (fr) * | 2000-11-30 | 2002-06-06 | Kissei Pharmaceutical Co., Ltd. | Derives de glucopyranosyloxybenzylbenzene, compositions medicinales contenant ces derives et produits intermediaires obtenus lors de l'elaboration de ces compositions |
| JP4035052B2 (ja) | 2000-12-28 | 2008-01-16 | キッセイ薬品工業株式会社 | グルコピラノシルオキシピラゾール誘導体及びその医薬用途 |
| TWI255817B (en) * | 2001-02-14 | 2006-06-01 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
| WO2003020737A1 (en) | 2001-09-05 | 2003-03-13 | Bristol-Myers Squibb Company | O-pyrazole glucoside sglt2 inhibitors and method of use |
| DE102004048388A1 (de) * | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
-
2004
- 2004-07-29 UA UAA200605348A patent/UA86042C2/ru unknown
- 2004-07-30 JP JP2006519250A patent/JP4717811B2/ja not_active Expired - Fee Related
- 2004-07-30 UA UAA200605349A patent/UA86599C2/ru unknown
- 2004-07-30 CN CN2010105463425A patent/CN102060888A/zh active Pending
- 2004-07-30 CN CNA2004800220063A patent/CN1829728A/zh active Pending
- 2004-07-30 NZ NZ545305A patent/NZ545305A/en not_active IP Right Cessation
- 2004-07-30 UA UAA200605347A patent/UA85569C2/ru unknown
- 2004-07-30 MX MXPA06001273A patent/MXPA06001273A/es active IP Right Grant
- 2004-07-30 ES ES04771313.6T patent/ES2527053T3/es not_active Expired - Lifetime
- 2004-07-30 US US10/566,585 patent/US7521430B2/en not_active Expired - Fee Related
- 2004-07-30 KR KR1020067002158A patent/KR101101500B1/ko not_active IP Right Cessation
- 2004-07-30 EP EP04771313.6A patent/EP1654269B1/en not_active Expired - Lifetime
- 2004-07-30 UA UAA200602256A patent/UA83377C2/uk unknown
- 2004-07-30 EA EA200600348A patent/EA011025B1/ru not_active IP Right Cessation
- 2004-07-30 CA CA2534022A patent/CA2534022C/en not_active Expired - Fee Related
- 2004-07-30 TW TW093122844A patent/TWI377209B/zh not_active IP Right Cessation
- 2004-07-30 WO PCT/JP2004/011311 patent/WO2005012321A1/en active Application Filing
- 2004-07-30 UA UAA200605346A patent/UA87991C2/ru unknown
- 2004-07-30 BR BRPI0413233-5A patent/BRPI0413233A/pt not_active IP Right Cessation
- 2004-07-30 AU AU2004260760A patent/AU2004260760B2/en not_active Ceased
-
2006
- 2006-01-10 IL IL173051A patent/IL173051A/en not_active IP Right Cessation
- 2006-01-16 NO NO20060219A patent/NO333679B1/no not_active IP Right Cessation
- 2006-02-27 ZA ZA200601686A patent/ZA200601686B/en unknown
- 2006-05-15 ZA ZA200603880A patent/ZA200603880B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2527053T3 (es) | 2015-01-20 |
| CA2534022C (en) | 2012-10-02 |
| CA2534022A1 (en) | 2005-02-10 |
| UA83377C2 (uk) | 2008-07-10 |
| EA200600348A1 (ru) | 2006-08-25 |
| ZA200601686B (en) | 2007-05-30 |
| JP4717811B2 (ja) | 2011-07-06 |
| NO333679B1 (no) | 2013-08-05 |
| UA86599C2 (en) | 2009-05-12 |
| EP1654269B1 (en) | 2014-10-15 |
| AU2004260760A1 (en) | 2005-02-10 |
| UA87991C2 (en) | 2009-09-10 |
| TWI377209B (en) | 2012-11-21 |
| JP2007518682A (ja) | 2007-07-12 |
| KR20060132539A (ko) | 2006-12-21 |
| ZA200603880B (en) | 2010-01-27 |
| TW200510440A (en) | 2005-03-16 |
| KR101101500B1 (ko) | 2012-01-03 |
| NZ545305A (en) | 2008-11-28 |
| EA011025B1 (ru) | 2008-12-30 |
| WO2005012321A1 (en) | 2005-02-10 |
| AU2004260760B2 (en) | 2009-08-13 |
| EP1654269A1 (en) | 2006-05-10 |
| CN102060888A (zh) | 2011-05-18 |
| BRPI0413233A (pt) | 2006-10-03 |
| US7521430B2 (en) | 2009-04-21 |
| IL173051A0 (en) | 2006-06-11 |
| IL173051A (en) | 2012-06-28 |
| UA85569C2 (ru) | 2009-02-10 |
| US20070060545A1 (en) | 2007-03-15 |
| MXPA06001273A (es) | 2006-04-11 |
| CN1829728A (zh) | 2006-09-06 |
| UA86042C2 (en) | 2009-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20060219L (no) | Forbindelser | |
| UA83243C2 (ru) | Соединения, которые ингибируют натриезависимый переносчик глюкозы | |
| EA200600925A1 (ru) | Производные триазола в качестве антагонистов вазопрессина | |
| DE60107449D1 (de) | Substituierte aminopropoxyarylderivate als lxr agonisten | |
| EA200601852A1 (ru) | Тетрагидрохинолиновые производные и способ их получения | |
| EA200602170A1 (ru) | Производные пиперидина, композиции на их основе, способы их применения | |
| AP1902A (en) | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials | |
| CY1111481T1 (el) | Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης | |
| EA200601235A1 (ru) | Производные тиазола | |
| ATE353870T1 (de) | Dibenzylaminverbindung und deren medizinische verwendung | |
| LU92113I2 (fr) | Perampanel et ses dérivés pharmaceutiquement acceptables (FYCOMPA) | |
| CY1112991T1 (el) | ΠΑΡΑΓΩΓΑ ΙΝΔΟΛΗΣ Ή ΒΕΝΖΙΜΙΔΑΖΟΛΗΣ ΓΙΑ ΤΗ ΡΥΘΜΙΣΗ ΤΗΣ ΙκΒ ΚΙΝΑΣΗΣ ΚΑΙ ΕΝΔΙΑΜΕΣΑ ΠΡΟΪΟΝΤΑ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΤΟΥΣ | |
| DK1210344T3 (da) | Heteropolycykliske forbindelser og anvendelser deraf som metabotrope glutamatreceptorantagonister | |
| NO986055D0 (no) | Nye heterocykliske forbindelser, deres fremstilling, farmas÷ytiske preparat | |
| HK1069395A1 (en) | Phthalazinone derivatives 2,3 | |
| ATE424393T1 (de) | 3-substituierte 4-pyrimidonderivate | |
| UA81561C2 (en) | Use of n-arylhydrazine derivative and method for controlling non-crop pests | |
| DE602004020730D1 (de) | Pharmazeutisches verfahren und damit hergestellte verbindungen | |
| AR045791A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina | |
| ATE453389T1 (de) | Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen | |
| NO20063111L (no) | Fremgangsmate for fremstilling av tiazolpyrimidiner | |
| NO20062965L (no) | NK-1-Reseptorantagonister | |
| NO20052023L (no) | Kalsium aktivert K kanal apner med hoy konduktans | |
| NO20023298D0 (no) | Nye imidazolderivater | |
| AR027035A1 (es) | Pirroles sustituidos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: MITSUBISHI TANABE PHARMA CORP, JP |
|
| MM1K | Lapsed by not paying the annual fees |